These work by reducing inflammation, but they're typically only used when symptoms are very bothersome
In contrast, canakinumab was associated with more gastrointestinal disorders (abdominal pain, mouth ulceration, and inflammatory bowel disease) and respiratory disorders (cough, oropharyngeal pain, and rhinorrhea)
For patients with Long COVID or ME/CFS, practitioners often recommend starting with a smaller dose (e.g., 1/4 or 1/2 scoop) to assess tolerance, as rapid detoxification can sometimes cause a temporary exacerbation of symptoms (a Herxheimer reaction) as toxins are mobilized
SURMOUNT-4, published in JAMA , showed that patients who continued tirzepatide maintained a 21.4% weight loss versus 14% regain in those switched to placebo
The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism
The general scheme of thiol-disulfide redox equilibria (as depicted in Fig